Following discontinuation of its primary commercial product in the U.S., Titan has pivoted to exploring strategic alternatives including potential mergers and business combinations. The company maintains its proprietary ProNeura implant technology platform with early-stage pipeline candidates, though the company experienced a significant business transformation with a merger completion in October 2025.
Cyborg Score Rationale
Titan faces significant headwinds with discontinued U.S. product commercialization, minimal market capitalization (~$3-5M), and a completed merger in October 2025 with Black Titan Corporation that resulted in NASDAQ trading cessation. The company remains early-stage for most pipeline programs with limited revenue generation.
Top Insights
Company completed merger with Black Titan Corporation in October 2025; original TTNP shares ceased trading on NASDAQ with Black Titan shares anticipated to begin trading
ProNeura platform technology remains proprietary asset with early-stage pipeline candidate TP-2021 for chronic pruritus in non-clinical development
Historical product Probuphine continues commercialization internationally (EU as Sixmo) by third-party licensee after Titan divested rights
Stock experienced significant volatility with 52-week range of $2.30-$23.48 as of end-2025, indicating high speculative trading activity
Named Competitors
Buprenorphine products — Leading buprenorphine for opioid use disorder